Radiancy psoriasis therapy:
This article was originally published in Clinica
Executive Summary
The US FDA has given Radiancy 510(k) clearance to market its phototherapy for psoriasis, which is based on its proprietary Light Heat Energy technology. The psoriasis light unit assembly (LUA) has been shown in clinical studies to be a safe and effective treatment for mild to moderate plaque and guttate psoriases, said the Orangeburg, New York firm; patients in the study showed an average reduction of 65% on the Psoriasis Severity Index (PSI). Radiancy said that LHE-based phototherapy systems were already cleared in the US for removing hair and treating acne vulgaris and pigmented and vascular lesions on all skin types and that the modular psoriasis LUA could be attached quickly to the systems.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.